A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...

The biotech firm launched the Phase Ib trial of Tune-401 in New Zealand and Hong Kong, making it the first pipeline candidate to enter clinical trials.

Researchers hope to test the product's ability to clear symptoms in patients with the rare genetic disorder driven by RPS19 ...

The Phase II trial could provide registrational data on Treos' peptide immunotherapy and Junshi's PD-1 inhibitor in MSS colorectal cancer.

A recent paper has shed more light on how corticosteroids frequently prescribed to lung cancer patients could inhibit the ...

Aster adds a longitudinal dataset from more than 400,000 cancer patients to Zephyr's AI and omics capabilities.

Not all patients are able to access the battery of tumor sequencing, liquid biopsy, and immunohistochemistry testing needed to assess HER2 biomarkers.

Kyverna is pursuing myasthenia gravis as a second indication for KYV-101 after stiff-person syndrome, for which it has already launched a pivotal study.

Based on preliminary Phase I data from 21 patients, the firm hopes to eventually pursue accelerated approval for MT-601.

The firm is advancing a Phase III confirmatory trial of Modeyso to potentially expand its use into newly diagnosed glioma patients.

Collaborators from various institutions will leverage the latest multidisciplinary drug development tools to produce tailored treatment and prevention strategies.

Researchers led by the nonprofit 4YouandMe and Mount Sinai want to identify second-site suppressor mutations as drug targets ...